Castilla-La Mancha acquires supply of nirsevimab for VRS for over €3.2 million

Castilla-La Mancha has authorized a supply contract for the monoclonal antibody nirsevimab (Beyfortus, from AstraZeneca) against the disease caused by respiratory syncytial virus (RSV), aimed at immunizing newborns and infants during the 2023-2024 season, in the amount of More than 3.2 million euros.

The district made the announcement at a governing council press conference on August 30.

Spokesperson for the Castilla-Manchego Administration, Esther PadillaRSV is a leading cause of lower respiratory tract infections in children under one year of age, especially those associated with bronchiolitis and pneumonia, as well as in the adult population over 65 years of age and those at risk, explained. In adults and older children, the infection may be asymptomatic or manifest as sinusitis or the common cold. In addition, babies may become fussy, have difficulty breathing, and become less active.

Therefore, Padilla insists that “it is imperative prevent diseasetake care of the health of all citizens, Reduce severe care burden This happens every winter in primary care services and hospitals.”

---

You may also like…